Eyes are on the rollout of Lilly's new weight loss pill.

The market leader in obesity shots, Lilly hasn’t made a major dent in the pill market yet.

With a share price of $1,182, Eli Lilly (LLY) is positioned for about 76% potential growth over the next three years in a ...

Hospitals now required to submit insurance claims data to qualify for discounts.

Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once.

Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.

The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, ...

Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory ...

By Maggie Fick and Andrew Silver BRUSSELS, June 24 (Reuters) - Eli Lilly's orforglipron type-2 diabetes and obesity pill could launch in China as soon as later this year, an executive at the U.S.

House committee launches investigation into Eli Lilly's China clinical trials at military hospitals and Xinjiang facilities, ...

LCCC is launching a hands-on training pipeline that places technicians directly into the pharmaceutical industry.